¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"High Potency Pain Reliever Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • labor pain
    ºÐ¸¸Åë(Áõ)
  • lightening pain
    Àü°ÝÅë(Áõ)
  • low back pain
    Ç㸮ÅëÁõ, ¿äÅë
  • myofascial pain dysfunction
    ±Ù¸·ÅëÁõ±â´ÉÀå¾Ö
  • myofascial pain syndrome
    ±Ù¸·ÅëÁõÁõÈıº
  • myofascial pain-dysfunction syndrome
    ±Ù¸·ÅëÁõ±â´ÉÀå¾ÖÁõÈıº
  • menstrual pain
    ¿ù°æÅë
  • neurogenic pain
    ½Å°æ¼ºÅëÁõ
  • ocular pain
    ´«ÅëÁõ
  • osteocopic pain
    »ÀÅëÁõ
  • occlusal pain
    ¸Â¹°¸²ÅëÁõ, ±³ÇÕÅëÁõ
  • pleuritic pain
    °¡½¿¸·¿°ÅëÁõ, È丷¿°ÅëÁõ
  • postprandial pain
    ½ÄÈÄÅëÁõ
  • prick pain
    Âñ¸²ÅëÁõ, ÀÚÅëÁõ
  • psychic pain
    ½É¸®ÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • myofascial click pain syndrome
    ±Ù¸·ÅëÁõÁõÈıº
  • occlusal pain
    ±³ÇÕÅë
  • ocular pain
    ´«ÅëÁõ
  • osteocopic pain
    °Ý½É°ñÅë, °Ý½É»À¾ÆÇÄ
  • pain
    ÅëÁõ
  • pain pathway
    ÅëÁõÀü´Þ·Î
  • pain reaction
    ÅëÁõ¹ÝÀÀ
  • pain sense
    Åë°¢, ¾ÆÇ°¨°¢
  • pain shock
    ÅëÁõ¼îÅ©
  • pain spot
    ÅëÁõÁ¡
  • pain surgery
    ÅëÁõ¿Ü°ú
  • paraplegic pain
    ¾çÇÏÁö¸¶ºñÅë
  • phantom limb pain
    ȯÁöÅë, ȯ»óÆÈ´Ù¸®ÅëÁõ
  • postprandial pain
    ½ÄÈÄÅëÁõ
  • prick pain
    ÀÚÅë, Âñ¸²ÅëÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
  • high spinal anesthesia
    °íÀ§Ã´Ã߸¶Ãë(¹ý).
  • high temperature sterlization
    °í¿Â¸ê±Õ.
  • high tension pulse
    °í¾Ð¸Æ(ÍÔäâØæ), °íÀ可(ÍÔí娿).
  • high tone deafness
    °íÀ½¼º³­Ã»
  • high tracheostomy
    »ó±â°üÀý°³¼ú
  • high vacuum
    °íÁø°ø(°íÁø°ø).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high ventricular septal defect
    °íÀ§½É½ÇÁ߰ݰá¼Õ.
  • high vitamin diet
    °íºñŸ¹Î½ÄÀÌ.
  • high voltage radiography
    °íÀü¾Ð ÃÔ¿µ¼ú
  • high volume sampler
    ÇÏÀ̺¼·ý»ùÇ÷¯.
  • high-altitude illness
    °í¼Ò¼ºÁúº´
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
  • high-performance liquid chromatography
    °íÀÛÀ§(íÂêÓ)¾×üũ·Î¸¶Åä±×¶óÇÇ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • oral cavity proper
    °íÀ¯ÀÔ¾È
  • oral cavity reconstruction
    ±¸°­Àç°Ç
  • oral cavity ³ª cavium oris
    ±¸°­(Ϣ˷).
  • oral character
    ±¸°­±â¼º°Ý, ±¸¾Ö¼º ¼º°Ý(Ï¢äñ àõàõÌ«).
  • oral cholecystography
    °æ±¸´ã³¶Á¶¿µ¼ú
  • oral contraception
    °æ±¸ÇÇÀÓ(ÌèÏ¢ù­ìô).
  • oral contraception
    °æ±¸ÇÇÀÓ(˭˴̰Ëö).
  • oral contraceptive
    °æ±¸¿ë(ÌèÏ¢éÄ) ÇÇÀÓ(ù­ìõ)¾à
  • oral contraceptive
    °æ±¸¿ë ÇÇÀÓÁ¦.
  • oral contraceptive
    °æ±¸(¿ë)ÇÇÀÓ¾à(ÌèÏ¢(éÄ)ù­ìôå·), °æ±¸ÇÇÀÓÁ¦(ÌèÏ¢ù­ìôð¥)
  • oral contraceptives
    °æ±¸ ÇÇÀÓÁ¦
  • oral deformity
    ±¸°­º¯Çü.
  • oral deformity
    ±¸°­º¯Çü(Ϣ˷ܨû¡)
  • oral dependence
    ±¸¼ø¼º ÀÇÁ¸.
  • oral diagnosis
    ±¸°­Áø´Ü(Ϣ˷òàÓ¨).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
MOPV monovalent oral poliovirus vaccine
OA obstructive apnea; occipital artery; occipito-anterior; occiput anterior; octanoic acid; ocular albi...
OA/BVM oral airway/bag-valve-mask
OAS old age security; oral allergy syndrome; osmotically active substance
OAW oral airways
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
CRPS-I Complex Regional Pain Syndrome Type I
CIPA Congenital Insensitivity to Pain with Anhidrosis
IASP International Association for the Study of Pain
LBP Low Back Pain
MPQ Mc Gill Pain Questionnaire
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • double pain
    ÀÌÁß Åë°¢
  • dream pain
    ¸ùÅë
  • dysesthetic pain
    °¨°¢ ÀÌ»ó¼º µ¿Åë
  • ear pain
    ÀÌÅë
  • early sharp pain
    ÃʱâÀÇ ¿¹¸®ÇÑ ÅëÁõ, ÃʱâÀÇ ¿¹¸®ÇÑ µ¿Åë
    Á¶Á÷ÀÇ ¼Õ»ó ½Ã¿¡ ¿©·¯ ½Å°æ¼¶À¯Áß A¥ä¼¶À¯°¡ ¸ÕÀú ½Å°æÀü´ÞÀ» ÇàÇϴµ¥ ÀÌ´Â ºü¸£°í ³¯Ä«·Î¿î ÅëÁõÀ» º¸ÀδÙ. ÀÌÈÄ¿¡ ´À¸®°í ¹¬Á÷ÇÑ ÅëÁõÀÌ ¿À´Â C ¼¶À¯°¡ Àü´ÞÀ» ÇàÇÑ´Ù.
  • elbow joint pain
    ÆÈ±Á °üÀýÅë
  • endogeneous pain-relief mechanisms
    ³»Àμº µ¿Åë ¿ÏÈ­ ±âÀü
  • expulsive pain
    ¹èÃâÅë
    ºÐ¸¸ Á¦2±âÀÇ µ¿Åë.
  • face pain
    ¾È¸éÅë
  • facial pain
    ¾È¸é ÅëÁõ, ¾È¸é µ¿Åë, ¾È¸éÅë
    Ä¡°ú Àǻ翡°Ô ¾È¸é µ¿ÅëÀÇ Áø´ÜÀº ¸Å¿ì ¾î·Á¿î ÀÏÀÌ´Ù. ¾È¸éºÎ µ¿ÅëÀÇ ¼º°øÀû Áø´ÜÀº Á¤È®Çϰí ÀÚ¼¼ÇÑ µ¿ÅëÀÇ º´·Â°ú ¾È¸é°ú ¿¬°üºÎÀÇ ÀÚ¼¼ÇÑ ÀÓ»óÀû °Ë»ç ¹× ¾È¸é µ¿ÅëÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â Á¶°Ç¿¡ ´ëÇÑ ÇØ¹ÚÇÑ Áö½Ä¿¡ ´Þ·Á ÀÖ´Ù. ±¸°­°ú ¾È¸éÀÇ µ¿ÅëÀº Ä¡¼ºÀÏ ¼öµµ ÀÖ°í ¶Ç´Â ºñÄ¡¼ºÀÏ ¼öµµ ÀÖ´Ù. ºÒÇÊ¿äÇÑ ¹ßÄ¡¸¦ ÇÏÁö ¾Ê±â À§Çؼ­ Á¤È®ÇÑ Áø´ÜÀ» ÇØ¾ß ÇÑ´Ù.
  • facial pain of unknown origin
    ¿øÀÎ ºÒ¸íÀÇ ¾È¸é ÅëÁõ, Àڹ߼º ¾È¸é ÅëÁõ
  • false pain
    °¡¼º µ¿Åë
    ºÐ¸¸ ÁøÅë°ú ºñ½ÁÇϳª È¿°ú°¡ ¾ø´Â ÁøÅëÀ¸·Î Àڱà °æ°ü È®ÀåÀÌ ÀϾÁö ¾Ê´Â´Ù.
  • flank pain
    Ãøº¹ºÎ ÅëÁõ, Ãøº¹Åë
  • headache pain
    µÎÅë
  • heat pain
    ¿­Åë
    °¡¿­À̳ª ³Ã°¢¿¡ ´ëÇØ ÇǺΰ¡ ÀÏÁ¤ ¿ªÄ¡ ÀÌ»óÀÎ °æ¿ì Åë°¢À¸·Î ÀÎÁöÇØ ÅëÁõÀ» ´À³¢´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
high blood pressure <cardiology> Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension).
This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
(29 Sep 1997)
high blood triglyceride <biochemistry> Elevation of triglycerides, a fatty substance found in the bloodstream. Normal triglyceride blood levels should be 10-150 milligrams per decilitre. Elevations of the triglyceride level (particularly in association with elevated cholesterol) have been correlated with the development of atherosclerosis, the underlying cause of heart disease and stroke.
Origin: Gr. Haima = blood
(27 Sep 1997)
high-bred Bred in high life; of pure blood.
Source: Websters Dictionary
(01 Mar 1998)
high-calorie diet A diet containing upward of 4,000 calories per day.
(05 Mar 2000)
high convex The segment of a sphere of short radius.
(05 Mar 2000)
high density lipoprotein <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream.
Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease).
Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women.
Acronym: HDL
(18 Nov 1997)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
high-egg-passage vaccine Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats.
(05 Mar 2000)
high endothelial postcapillary venules Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma.
(05 Mar 2000)
high enema An enema instilled high up into the colon.
Synonym: enteroclysis.
(05 Mar 2000)
high energy bond <chemistry> Chemical bonds that release more than 25kJ/mol on hydrolysis: their importance is that the energy can be used to transfer the hydrolysed residue to another compound. The risk in using the term is that students may think the bond itself is different in some way, whereas it is the compound that matters. Hydrolysis of creatine phosphate yields 42.7kJ/mol, of phosphoenolpyruvate, 53.2, ATP to ADP, 30.5: the latter is important because it shows that energetically the hydrolysis of creatine phosphate will suffice to reconstitute ATP, hence the use of creatine phosphate in muscle.
(18 Nov 1997)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
high energy phosphate bond See: high energy phosphates.
(05 Mar 2000)
high energy phosphates Those phosphate's that, on hydrolysis, yield an unusually large amount of energy; e.g., nucleotide polyphosphates such as ATP, enol phosphate's such as phosphoenolpyruvate.
See: high energy compounds.
Synonym: energy-rich phosphates.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á